Virtual Library

Start Your Search

Takashi Yokoi



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-112 - Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab (ID 13715)

      16:45 - 18:00  |  Presenting Author(s): Takashi Yokoi

      • Abstract

      Background

      Nivolumab, an anti-programmed cell death 1(PD-1) antibody, is a standard regimen for the second-line treatment of non-small cell lung cancer (NSCLC). However, compared with molecular-targeted drugs, the response rate to nivolumab is low, and biomarkers of efficacy are currently lacking. It has been recently reported that the neutrophil-to-lymphocyte ratio (NLR) can be a biomarker of efficacy. Here, we examined the possibility for NLR to predict efficacy of nivolumab.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We retrospectively examined all patients with NSCLC who were treated with nivolumab at our institution.

      4c3880bb027f159e801041b1021e88e8 Result

      We compared 35 patients with NLR of ≥3 and 44 with NLR of <3, all of whom were treated with nivolumab. There was no difference in response rates between the two groups. The median (m) PFS and mOS were 130 and 583 days in the NLR≥3 group, whereas those were 169 days and not reached (NR) in the NLR<3 group. Longer PFS and OS were observed in the NLR<3 group than in the NLR≥3 group. Next, we analyzed the relationship between treatment efficacy and relative change of NLR (NLR), the ratio of the value at 4 weeks after the administration of nivolumab to the value at baseline. In 42 patients with NLR of 1, mPFS and mOS were 122 and 564 days, respectively. In 31 patients with NLR of <1, mPFS and mOS were 280 days and NR, respectively. PFS and OS were significantly better in the group with NLR of <1. With respect to adverse events, grade 1-2 rashes were observed in 29% of patients in the group with NLR of <1 and in 9.5% of patients in the group with NLR of 1.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Relative ratio of NLR at 4 weeks/at baseline is a predictive biomarker in patients with NSCLC who are treated with nivolumab.

      6f8b794f3246b0c1e1780bb4d4d5dc53